Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of certain cytotoxic regimens. It is characterised by sensory symptoms such as numbness, tingling and neuropathic pain and motor symptoms such as decreased strength in the hands and feet. Prompt and accurate symptom management is important because persistent unrelieved symptoms interfere with activities of daily living and can affect patients’ emotional well-being and quality of life. To date, there has been no national guidance on CIPN to inform practice, and evidence suggests that the recognition and management of CIPN can be improved. Nurses have an important role in preparing and monitoring people who are at risk of CIPN, as well as in providing essential care and advice to those with symptoms.

This article summarises the results of a survey undertaken by one English Cancer Alliance that explored the management of CIPN in oncology services and the CIPN-related learning needs of oncology clinicians. The article details the local CIPN treatment guidelines devised following the survey. It also outlines information and advice on the assessment and management of patients with CIPN.